2024年11月7日,专门从事癌症检测业务的医疗科技公司Guardant Health Inc.(股票代码:GH)在盘前大涨31%,引发市场广泛关注。在没有重大事件新闻的情况下,此轮涨幅主要受到分析师机构利好评级预期的推动。
分析师报告显示,机构投资者普遍看好Guardant Health公司未来几年的业绩增长前景。该公司在液体活检等创新医疗检测领域处于行业领先地位,疫情影响逐步减弱后,预计相关服务需求将大幅增长,Guardant Health将从中获益。
与此同时,Guardant Health当天上调了2024财年的营收预期,预计营收将在7.2亿至7.25亿美元区间,比此前6.9亿至7亿美元的预期有所增长,也向市场传递了积极信号。具体来看,摩根大通将其目标价从48美元上调至50美元,而Leerink Partners则将目标价从50美元上调至60美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.